Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
2025 · 1st Quarter (Jan 1 - Mar 31)
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY)
Filed by TIBER CREEK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 17, 2025
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK GROUP
- Filing UUID
- 18c6ec36-1ec1-446a-a5e1-e020ec8f452a
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023.
Issues related to intellectual property; S. 150 - Affordable Prescriptions for Patients Act of 2023; H.R. 6986/S. 3583 - A Bill to Address Patent Thickets.
Literal federal measure citations: S. 150, H.R. 6986, S. 3583
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.